Renaissance Group’s Corcept Therapeutics CORT Stock Holding History

Renaissance Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-20,381	Closed	-$368K	–	285
2017 Q4	$368K	Buy	+20,381	New	+$369K	0.01%	246

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Group's CORT Position: Q1 2018 in Review

Renaissance Group sold out of Corcept Therapeutics (CORT) in Q1 2018, closing a stake of 20,381 shares — an estimated $368K sold.

Renaissance Group first reported a position in CORT in Q4 2017 and held it in 1 quarter. The position peaked at $368K in Q4 2017. 212 funds tracked by Wall St. Rank hold CORT as of Q1 2018.

Renaissance Group reported no remaining Corcept Therapeutics position as of Q1 2018 after selling out during the quarter.
Renaissance Group sold 20,381 Corcept Therapeutics shares in Q1 2018, an estimated $368K.
Renaissance Group first reported a position in Corcept Therapeutics in Q4 2017 and held it in 1 quarter.
Renaissance Group's Corcept Therapeutics position peaked at $368K in Q4 2017.
212 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2018.

Based on Renaissance Group's 13F filing for Q1 2018, filed 30 Apr 2018.